The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Enough cash to last until 2009. A promising drug in Phase I trials. Run by a madly ambitious Rhodes Scholar. Technology from some of the world's greatest chemists AND the developer of Velcade. A technique for developing small-molecule drugs with some of the complex folding of actual proteins. A very experienced team, mostly from Millenium. And, if you subtract out the cash they will have on hand early next quarter, you can buy all of this for less than the money already invested by venture capitalists.
INFI on 9/17/07 received orphan drug status from the FDA for their cancer drug protecting INFI from major competition for at least seven years.